Peaceful Presence
HomeAboutServicesTMS & SpravatoFAQContactResourcesCollaborate
Get in touchCall (714) 584-7707
← Resources

Ketamine Troches vs. Spravato vs. IV Ketamine: Understanding Your Treatment Options for Depression

Charles Scribner
Charles Scribner, PMHNP-BC
November 15, 2026 · 12 min read · Treatments
Three quiet paths branching from one point in a sunlit Southern California park.

When you've been struggling with depression, especially after trying different medications or therapies without getting the relief you hoped for, it can be discouraging.

Over the years, I've worked with patients who have done everything they were supposed to do. They've tried medications, attended therapy, made lifestyle changes, and yet still find themselves struggling.

Fortunately, our understanding of depression continues to evolve, and so do our treatment options.

One area that has received considerable attention is ketamine-based treatment. You may have heard about IV ketamine infusions, Spravato nasal spray, or ketamine troches that dissolve in your mouth.

Although these treatments are related, there are important differences in how they work, how they are administered, their safety requirements, and how much they may cost.

I want to help you understand these differences so you can make an informed decision about what might be appropriate for you.

How is ketamine different from traditional antidepressants?

Most traditional antidepressants, including SSRIs and SNRIs, primarily influence chemicals such as serotonin and norepinephrine.

Ketamine works differently. It affects a brain signaling system involving glutamate, a neurotransmitter involved in learning, memory, and how brain cells communicate.

This different mechanism is part of what makes ketamine-based treatments interesting for people with treatment-resistant depression.

Some patients experience improvements much sooner than they would with traditional antidepressants, sometimes within hours or days [2]. However, not everyone responds, and improvements may be temporary without an appropriate ongoing treatment plan.

There are three approaches worth understanding.

1. Spravato: An FDA-approved treatment with potential insurance coverage

Spravato (esketamine) is a prescription nasal spray that has been FDA-approved for specific depression indications in adults.

It is approved for treatment-resistant depression, either by itself or alongside an oral antidepressant. It is also approved, in combination with an oral antidepressant, for depressive symptoms in adults with major depressive disorder experiencing acute suicidal ideation or behavior [1].

Unlike compounded ketamine formulations, Spravato has undergone FDA review for these indications and has established treatment and monitoring requirements.

Why I find Spravato particularly valuable

One of the biggest advantages of Spravato is that many insurance plans may cover treatment when medical necessity requirements are met.

This is important because access to treatment matters.

I've seen how financial limitations can influence someone's ability to pursue or continue mental health care. A treatment may be clinically promising, but if someone cannot realistically afford the initial appointments or ongoing treatment, that becomes a significant barrier.

IV ketamine infusions, for example, frequently require patients to pay out of pocket. Spravato offers another potential pathway.

Insurance coverage is never automatic. Approval may depend on your diagnosis, previous medication trials, treatment history, insurance benefits, and prior authorization requirements. Patients may still have deductibles, copays, or coinsurance.

But for someone who qualifies, coverage can make a meaningful difference in the affordability of treatment.

What does Spravato treatment look like?

Spravato is administered as a nasal spray in a certified healthcare setting under medical supervision.

After receiving treatment, patients remain for at least two hours while their blood pressure, breathing, alertness, and overall response are monitored [1].

Patients need transportation home and cannot drive until the following day after a restful night's sleep [1].

Treatment generally begins with twice-weekly visits for the first four weeks, followed by less frequent appointments based on response and clinical needs [1].

Spravato is not something patients take home or administer independently.

I view the structured clinical setting as a benefit for appropriate patients because it allows us to monitor both treatment response and potential side effects.

Possible side effects include dissociation, sedation, dizziness, nausea, increased blood pressure, and, in some cases, respiratory depression [1]. Careful screening and monitoring are essential.

2. IV ketamine infusions: A promising option with a greater financial commitment

IV ketamine has been studied for depression for many years and has shown potentially rapid antidepressant effects in clinical research.

Unlike Spravato, IV ketamine for depression is used off-label. Although ketamine itself is FDA-approved for anesthesia, IV administration for depression has not received FDA approval for that indication [4].

During treatment, ketamine is administered directly into the bloodstream through an IV, typically in a medical setting with trained staff.

This allows the clinical team to control the rate of administration and monitor the patient's response.

Why might someone choose IV ketamine?

For some patients, IV ketamine may be worth exploring when other treatments have not provided adequate improvement.

Research suggests it can produce relatively rapid antidepressant effects in certain patients with treatment-resistant depression [2][3].

However, the response varies, and improvements after an infusion or initial series do not necessarily last indefinitely.

A treatment plan needs to address both initial improvement and what happens afterward.

The biggest challenge: Cost and ongoing treatment

One of the main disadvantages of IV ketamine for depression is that it is often not covered by insurance.

Many clinics operate on a cash-pay basis, and an initial series of infusions can represent a significant expense. Maintenance treatments, when recommended, can add to that cost.

For patients who respond well, this creates an important question:

What happens when treatment helps, but continuing regular infusions becomes financially difficult?

This is one reason I believe patients should understand all their options before committing to a particular approach.

IV ketamine may be appropriate for certain individuals, but cost, safety, access, and long-term planning all deserve consideration.

3. Ketamine troches: A more convenient, potentially lower-cost option

Ketamine troches are compounded lozenges that dissolve in the mouth, usually under the tongue or against the cheek.

Some patients may instead receive rapidly dissolving tablets, commonly called RDTs.

These are related formulations, but they are not necessarily identical in how they are made or absorbed.

Patients sometimes refer to troche treatment as low-dose ketamine, although doses and exposure vary substantially, and not every troche prescription is accurately described as low-dose.

Why are patients interested in troches?

For some patients, one of the main appeals is convenience.

Certain prescribing programs offer at-home administration, removing the need to travel to a clinic for every treatment.

The medication itself may also be less expensive than repeated IV infusions, depending on the pharmacy, formulation, prescribing program, and associated follow-up costs.

There is growing research exploring oral and sublingual ketamine for depression, and some patients report meaningful improvements.

However, an important distinction needs to be made.

Compounded ketamine troches are not FDA-approved treatments for depression [4].

The research supporting oral ketamine is evolving, but evidence from one formulation cannot automatically be applied to every compounded troche or rapidly dissolving tablet.

We also have less information about their long-term effectiveness and safety, particularly with repeated at-home use.

Why careful monitoring still matters

Just because a medication can be taken at home does not mean it should be approached casually.

Ketamine can affect blood pressure, alertness, perception, coordination, and judgment. It also carries risks related to misuse, dependence, and possible urinary or bladder complications with repeated exposure [4].

Patients should receive an appropriate psychiatric and medical evaluation, understand the potential risks, and have a clear plan for follow-up and monitoring.

For me, the larger question isn't simply whether ketamine troches are convenient or affordable.

It's whether this approach is appropriate, safe, and sustainable for the individual patient.

Comparing ketamine treatments

Spravato IV ketamine Ketamine troches
FDA-approved for depression Yes, for specific adult indications No No
Administration Nasal spray IV infusion Dissolving lozenge or tablet
Treatment setting Certified healthcare facility Supervised medical setting At home in some programs
Insurance coverage Possible with approval Often self-pay Usually self-pay
Monitoring At least 2 hours after each dose During and after infusion Depends on treatment program
Potential advantage FDA-reviewed evidence, structured monitoring, possible insurance coverage Direct administration and research supporting rapid antidepressant effects Convenience and potentially lower medication cost
Important limitation Appointment commitment and eligibility requirements Cost and uncertainty about maintaining response Less standardized evidence and limited long-term data

Can these treatments complement one another?

This is an interesting question, particularly when we think about long-term treatment planning.

Depression treatment is not always a straight line. Some patients respond to one treatment but struggle to maintain the improvement. Others may benefit from reassessing their approach as their circumstances change.

For example, imagine someone who experiences meaningful improvement during a series of IV ketamine infusions but finds the cost of ongoing treatment difficult to maintain.

One potential discussion with their psychiatric provider might be whether FDA-approved Spravato is appropriate and whether their insurance would cover it.

Similarly, some patients may ask whether a compounded ketamine formulation could play a role in future maintenance treatment.

These are reasonable questions to explore, but there are important limitations.

Moving from IV ketamine to Spravato, or from Spravato to ketamine troches, is not an established or universally recommended maintenance sequence.

We do not yet have strong evidence establishing that these treatments can routinely substitute for one another while preserving the same antidepressant response.

A patient who improves with one formulation will not necessarily experience the same benefit with another.

For treatment-resistant depression, Spravato itself has an FDA-labeled maintenance schedule that can be individualized according to clinical response [1].

That is particularly valuable because there is an established framework for continuing treatment beyond the initial phase.

Any consideration of switching approaches should involve an individualized evaluation of the patient's history, response, safety, and treatment goals.

The goal should never be simply to move patients from one ketamine formulation to another. It should be to find a treatment plan that provides meaningful improvement and can be maintained safely.

What treatment is best for depression?

I don't believe there is one treatment that makes sense for every patient.

Some patients may be appropriate candidates for Spravato. Others may want to explore IV ketamine or discuss compounded formulations with a qualified clinician. Still others may benefit more from a different medication, psychotherapy, transcranial magnetic stimulation (TMS), or a combination of approaches.

Before recommending any treatment, I want to understand what you've already tried, what has helped, what hasn't, and how depression is affecting your daily life.

I'm also interested in the bigger picture: your sleep, physical health, nutrition, relationships, stressors, and sense of purpose.

Depression doesn't exist in isolation from the rest of your life.

And while medication can be an important part of recovery, I believe the best care takes into account the whole person.

Frequently asked questions

Is Spravato covered by insurance?

Spravato may be covered by commercial insurance, Medicare, or other qualifying plans, depending on benefits and medical necessity criteria. Prior authorization is commonly required. Coverage and out-of-pocket costs must be verified individually.

Is Spravato the same thing as ketamine?

Spravato contains esketamine, one of the two molecular forms found in conventional ketamine. IV ketamine and compounded troches generally contain racemic ketamine, which includes both forms [1]. They are related but are not interchangeable treatments.

Is IV ketamine stronger than Spravato?

There is no simple comparison. The medications differ in administration, absorption, dosing, clinical evidence, and monitoring. A treatment that works well for one person may not work as well for another.

Are ketamine troches cheaper than IV infusions?

They can be. The compounded medication itself is often less expensive than an infusion, but the total cost also depends on psychiatric assessments, monitoring, follow-up visits, and the prescribing program.

Can someone switch from IV ketamine to Spravato?

A person who has received IV ketamine may be evaluated for Spravato if they meet the appropriate clinical criteria. A previous response to IV ketamine does not guarantee a response to Spravato, and insurance approval is not automatic.

Can low-dose ketamine troches be used for maintenance?

Some clinicians prescribe compounded ketamine formulations in this way, but maintenance treatment with troches is not FDA-approved for depression, and long-term evidence is limited. It requires individualized assessment, risk discussion, and appropriate monitoring.

A final thought: Treatment should be individualized and accessible

One thing I've learned throughout my years in mental health care is that recovery looks different for everyone.

Some people respond well to traditional antidepressants. Others continue struggling despite trying several medications and making considerable efforts to improve their mental health.

For those individuals, emerging and newer treatment approaches may offer additional possibilities.

I'm particularly encouraged by Spravato because it combines an FDA-approved treatment approach with the possibility of insurance coverage, which may help make treatment accessible to more patients.

At the same time, I recognize that IV ketamine and other formulations are areas of ongoing clinical interest.

My priority is helping patients understand their options, make informed decisions, and develop a treatment plan that is safe, realistic, and centered on meaningful improvement.

At Peaceful Presence Mental Health in Brea, California, we provide thorough psychiatric evaluations and individualized depression treatment planning.

If you've been struggling with depression despite previous treatments, an evaluation can help us explore which options may be appropriate for you.

Medical disclaimer: This article is intended for educational purposes and is not a substitute for medical advice. Treatment eligibility, safety, availability, and insurance coverage are determined individually. If you are experiencing a mental health crisis, call or text 988. For an immediate emergency, call 911.

References

  1. Janssen Pharmaceuticals. SPRAVATO (esketamine) nasal spray. Full prescribing information, revised March 2026. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf
  2. Sanacora G, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 2017. https://pubmed.ncbi.nlm.nih.gov/28249076/
  3. Anand A, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine, 2023. https://pubmed.ncbi.nlm.nih.gov/37224232/
  4. U.S. Food and Drug Administration. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. October 10, 2023. https://web.archive.org/web/20260530025451/https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine
Charles Scribner
Charles Scribner, PMHNP-BC

Psychiatric nurse practitioner in Brea, CA. Sixteen years at the bedside. It starts with a free 15-minute call.

Get in touch

More from Resources

Bipolar Disorder Treatment: What I Look For Before Prescribing
TreatmentsBipolar Disorder Treatment: What I Look For Before PrescribingRead →
Teen Psychiatry: What a First Visit Looks Like for Your Teen
TreatmentsTeen Psychiatry: What a First Visit Looks Like for Your TeenRead →
Therapist, Psychiatrist, or Psychiatric Nurse Practitioner: Who Does What for Anxiety and Depression?
TreatmentsTherapist, Psychiatrist, or Psychiatric Nurse Practitioner: Who Does What for Anxiety and Depression?Read →